Comparative Pharmacology
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE versus PROVENTIL HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE versus PROVENTIL HFA.
ISOETHARINE HYDROCHLORIDE vs PROVENTIL-HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ISOETHARINE HYDROCHLORIDE is a beta-2 adrenergic receptor agonist that stimulates adenylate cyclase, increasing cyclic AMP (cAMP) in bronchial smooth muscle, leading to bronchodilation. It also has beta-1 activity at higher doses, causing cardiac stimulation.
Selective beta2-adrenergic receptor agonist, relaxing bronchial smooth muscle via increased intracellular cAMP.
Inhalation via nebulizer: 0.5 mL (2.5 mg) of 0.5% solution diluted in 2-3 mL normal saline, administered over 10-20 minutes, every 4-6 hours as needed.
2 inhalations (90 mcg each) by oral inhalation every 4 to 6 hours as needed for bronchospasm. For prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
None Documented
None Documented
1.6 to 2.7 hours in adults; may be prolonged in patients with hepatic or renal impairment.
Terminal elimination half-life is 3.8-6 hours. In patients with hepatic impairment or elderly, half-life may be prolonged, requiring dose adjustment.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Approximately 60-70% of the dose is excreted renally as unchanged drug and metabolites after intravenous administration. Fecal excretion accounts for <10%.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist